ACTRN12617000993392尚未招募不适用
Clinical outcome of advanced EGFR-mutated NSCLC patients who developed acquired resistance to first generation EGFR inhibitors with positive plasma T790M treated with osimertinib in NSW, Australia.
Medical Oncology Department, Liverpool Hospital0 个研究点目标入组 66 人开始时间: 2017年7月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 —（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
不适用
EGFR testing (A molecular test) in advanced Lung cancer in patients treated with radiation therapy.CTRI/2017/05/008651ot Applicable150
招募中
不适用
Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLCLung Cancer (NSCLC)NCT06771960Guangdong Provincial People's Hospital120
招募中
3 期
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNCT05800223Shanghai Cancer Hospital, China300
暂停
2 期
Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT02470065European Organisation for Research and Treatment of Cancer - EORTC38
已完成
2 期
Iressa RE-challenge in advanced NSCLC EGFR mutated patients who responded to an EGFR-TKI used as first-line or previous treatment. NVALT 16Lung cancer. Pulmonary carcinoma10038666NL-OMON41485VALT92